After approval was obtained in October 2018, the kidney transplantation study with RESCAP® platform technology under supervision of PI Dr Joost van der Heijden from VUmc Amsterdam found its “First Patient In” status in June 2019. Ischemic injury in kidneys to be transplanted are cause of serious complications and limit overall success rate of transplantation. With RESCAP® we expect to reduce overall SIRS complication s peri-and post surgery and expect to improve patients well being following surgery. A follow up study is planned with non-heart beating donor kidneys as soon as this study is finalised in a multi-center approach
Alloksys announces first patients enrolled in the continuation of the APPIRED III clinical trial with RESCAP® in patients undergoing cardiothoracic surgery
October 1, 2024. Alloksys anticipates that in the just started continuation of the APPIRED III study (a placebo-controlled combined phase IIb / III trial), with